Biomarkers predicting the controller dose of omalizumab in patients with chronic spontaneous urticaria

Author:

Zubiaga‐Fernandez L.1,Testera‐Montes A.12,Rondon C.12ORCID,Perez‐Sanchez N.12,Gomez‐Perez F.12,Vega‐Chicote J. M.1,Bartra J.23,Ferrer M.24ORCID,Eguiluz‐Gracia I.12ORCID,Torres M. J.125

Affiliation:

1. Allergy Department, Allergy Unit Hospital Regional Universitario de Malaga and Instituto de Investigacion Biomedica de Malaga (IBIMA)‐Plataforma BIONAND Malaga Spain

2. RICORS de Enfermedades Inflamatorias (ISCIII) Madrid Spain

3. Pulmonology Department, Allergy Section Hospital Clinic and IDIBAPS Barcelona Spain

4. Department of Allergy Clinica Universidad de Navarra Pamplona Spain

5. Department of Medicine and Dermatology Universidad de Malaga Malaga Spain

Abstract

AbstractBackgroundClinical trials showed the efficacy of 300 mg/4 weeks of omalizumab (OMA) during 6 months in patients with severe chronic spontaneous urticaria (CSU). Nevertheless, in real life, many patients require higher doses and/or longer treatment. This study assesses the real‐life performance of OMA in severe CSU and identifies factors associated with the response.MethodsCSU patients eligible for OMA were recruited prospectively. Clinical data and a blood test were collected before OMA initiation. Urticaria Activity Score 7 (UAS7) was calculated at baseline and every 3 months during OMA treatment. CSU control was defined as UAS7 <7 points. This work was partially sponsored by OMA manufacturer.ResultsEighty‐nine adults (19.1% males) with severe CSU were recruited. Median duration of CSU prior to OMA initiation was 2 years, and median severity by UAS7 at baseline was 24 points (range 10–42 points). OMA controlled 94.4% of patients, but 17.9% of responders required doses >300 mg/4 weeks. A blood basophil count >20 cells/μL (OR 13.33; 95% CI 3.32–52.63; p < .001) and the absence of hypothyroidism (OR 3.65; 95% CI 0.78–16.95; p = .099) were identified as predictive factors to achieve control with 300 mg/4 weeks. Twelve patients were able to stop OMA during the study (responders in remission, RR). RR had received OMA for a median of 29 months (12–53 months). Conversely, 32 patients had been on OMA for >29 months at the end of the study (active responders, AR). AR had received OMA for a median of 45 months (30–100 months). There were no significant differences in clinical or analytical factors between RR and AR patients.ConclusionsLow blood basophil count and the presence of hypothyroidism might serve as biomarkers for the controller dose of OMA in severe CSU patients.

Funder

Instituto de Salud Carlos III

Novartis Pharmaceuticals Corporation

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3